कोशिश गोल्ड - मुक्त

SARS-CoV-2: A Biochemical Treatise on its Past, Present & Future

Bio Spectrum

|

September 2021

The SARS-CoV-2 pandemic is unprecedented but equally unprecedented is the contribution of scientists who have helped us in understanding the mechanisms by which it infects human beings and also, developing a variety of vaccines to protect the masses, in a year’s time, which can be called truly groundbreaking. This article gives an overview of the progress made by scientists around the world working round the clock in developing an understanding of the SARS-CoV-2 evolution and COVID-19 disease pathogenesis, and also makes an attempt to suggest the possible ways of coping with this pandemic if we have to co-exist with it forever!

- Dr Ashok Kumar

SARS-CoV-2: A Biochemical Treatise on its Past, Present & Future

As per the figures disclosed by the National Health Ministry (NHM), India has witnessed 400,000 excess deaths in April and May, 2021 in comparison with April and May 2020. And the surge in COVID-19, cases in Europe, the US and neighbouring countries reveals that the coronavirus is still amidst us and is thriving well! Since December 2019, with more than 188 million confirmed cases and more than 4.0 million deaths worldwide, as recorded on July 16, 2021, COVID-19 has severely disrupted human life, and we still don’t know for sure. The reasons why COVID-19 drastically affects some people, but the majority recovers whilst remaining largely asymptomatic. ‘How long will the immunity acquired after infection or the vaccination driven adaptive immunity be able to save us from reinfection?’ is a million-dollar question.

Why is SARS-CoV-2 so contagious?

Expedited sequencing of the viral genome, which proved that SAR-CoV-2 is similar to SARS (Severe Acute Respiratory Syndrome), the infection broke out in China between 2002 and 2004, also provided a clear understanding about the nature and mechanism by which SARS-CoV-2 spikes bind with Angiotensin-Converting Enzyme-2 (ACE-2), 10-20 times more effective than its predecessor, and how it gets quickly detached with the help of a protease allowing the lipid layer to fuse with the cell membrane and releasing its RNA into the host cell. Once inside, the virus replicates by simply hijacking the machinery of the host cells, thus spreading further and infecting more cells and eventually other organs, the transmission contaminating the environment and thus infecting more people. It’s again the understanding of the spike glycoproteins, which formed the basis for developing novel vaccines, in record times.

Bio Spectrum से और कहानियाँ

Bio Spectrum

Bio Spectrum

WHO certifies Suriname malaria-free

Suriname became the first country in the Amazon region to receive malaria-free certification from the World Health Organization (WHO).

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Torrent Pharma buys controlling stake in JB Pharma from KKR for Rs 25,689 Cr valuation

Ahmedabad-based Torrent Pharmaceuticals and global investment firm KKR have announced that Torrent has entered into definitive agreements to acquire controlling stake in Mumbai-based J. B. Chemicals and Pharmaceuticals (JB Pharma) from KKR at an Equity Valuation of Rs 25,689 crore (on fully diluted basis), followed by a merger of the two entities.

time to read

1 min

August 2025

Bio Spectrum

Suraksha Diagnostics injects Rs 22 Cr to establish Eastern India's largest genomics lab

Suraksha Diagnostics, one of the leading diagnostics chains in Eastern India, has launched one of the largest and a state-of-theart genomics lab in Eastern India.

time to read

1 min

August 2025

Bio Spectrum

Illumina buys SomaLogic for $425 M to accelerate proteomics business

Illumina, Inc. has entered into a definitive agreement with Standard BioTools under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Kashmik Formulation to expand capacity, eyes Rs 100 Cr revenue in FY26

Kashmik Formulation, a pharmaceutical manufacturing company headquartered in Ahmedabad, has announced significant expansion plans aimed at increasing production capacity, strengthening its presence in international markets, and enhancing operational efficiencies through automation.

time to read

1 min

August 2025

Bio Spectrum

WHO highlights risks associated with use of semaglutide medicines

The World Health Organisation (WHO) is alerting healthcare professionals and regulatory authorities to the risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of semaglutide medicinesOzempic, Rybelsus, and Wegovy.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Lamark Biotech secures Rs 6.5 Cr to accelerate development of thermostable insulin

Lamark Biotech, an innovation-led biopharma startup, has raised Rs 6.5 crore in a PreSeries A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Dr Vinayender Tulla, Dr Nita Roy, and Venkataraman KNK, domain experts of IAN's angel investors led the round.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

AstraZeneca invests Rs 166 Cr to expand Global Hub in Bengaluru

AstraZeneca, a global, science-led biopharmaceutical company, has announced the expansion of its state-of-the-art Global Hub in Bengaluru, strengthening its presence in India.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Novo Nordisk launches injectable Semaglutide for weight management in India

Novo Nordisk, a leading global healthcare company headquartered in Denmark with over a 100-year legacy of chronic disease care, has announced the launch of Wegovy (injectable Semaglutide) in India.

time to read

1 min

August 2025

Bio Spectrum

Bio Spectrum

Can Policy Reforms & Investments Trigger India's MedTech MAKEOVER?

India's MedTech sector has long been import-dependent. The Centre is now working to change this by positioning the country as an export-oriented manufacturing hub. A series of policies and investments have been introduced to support this shift. Have these made an impact? What steps are necessary to strengthen India's position in the global medical technology (MedTech) landscape? Let's find out.

time to read

12 mins

August 2025

Translate

Share

-
+

Change font size